HealthcareServices

Post-Operative Nausea And Vomiting Market Growth Projection: Expected to Surpass $3.12 Billion by 2030 at 6.7% CAGR

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the post-operative nausea and vomiting market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Post-Operative Nausea And Vomiting Market be in 2030 compared with 2026?

The market for post-operative nausea and vomiting has experienced significant expansion recently. This market is projected to expand from $2.25 billion in 2025 to $2.41 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this growth has been driven by several factors, including a rise in surgical procedure volumes, more extensive application of general anesthesia, the accessibility of serotonin antagonist medications, the development of hospital surgical facilities, and enhanced post-operative care protocols.

The post-operative nausea and vomiting market is projected for substantial expansion over the coming years, reaching $3.13 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.7%. This anticipated growth is linked to factors such as the increasing demand for personalized anesthesia care, greater adoption of preventive antiemetic regimens, the proliferation of ambulatory surgical centers, a heightened focus on patient satisfaction metrics, and increased investments in perioperative care innovation. Key developments expected during this period involve wider implementation of multimodal ponv management strategies, increased application of combination antiemetic therapies, a stronger emphasis on risk-stratified treatment protocols, the expansion of non-pharmacological interventions, and a greater commitment to patient comfort and recovery.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp

What Drivers Are Guiding Growth Patterns In The Post-Operative Nausea And Vomiting Market?

The increasing volume of surgical operations is anticipated to drive the expansion of the Post-Operative Nausea And Vomiting Market in the future. These procedures are medical interventions employing instruments to identify, address, or excise compromised tissues, organs, or irregularities through incision or manipulation. The surge in surgeries can be attributed to innovations in medical technology, making operations safer, more efficient, and less invasive, thereby enhancing patient acceptance and broadening their use. Effective management of post-operative nausea and vomiting improves surgical processes by boosting patient comfort, shortening recovery periods, lowering complication risks, facilitating seamless post-operative care, and ultimately leading to superior surgical results. For example, information from November 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government agency, showed that during the 2023–24 period, 771,600 patients were admitted for surgery from public hospital elective waiting lists, indicating a 4.9% rise compared to 2022–23. Consequently, the escalating number of surgical interventions is propelling the growth of the Post-Operative Nausea And Vomiting Market.

Which Segments Are Driving Activity In The Post-Operative Nausea And Vomiting Market?

The post-operative nausea and vomiting market covered in this report is segmented –

1) By Treatment Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment, Other Treatment Types

2) By Route Of Administration: Oral, Intravenous, Transdermal, Other Route Of Administrations

3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Surgical Procedure Type: Orthopedic Surgery, Gynecological Surgery, General Surgery, Cardiac Surgery, Ophthalmic Surgery

5) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Serotonin Antagonists Type: Ondansetron, Granisetron, Palonosetron, Dolasetron, Tropisetron

2) By Steroids Type: Dexamethasone, Methylprednisolone, Hydrocortisone, Prednisolone, Betamethasone

3) By Dopamine Antagonists Type: Metoclopramide, Droperidol, Prochlorperazine, Domperidone, Chlorpromazine

4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant, Fosaprepitant, Rolapitant, Netupitant, Casopitant

5) By Non-Pharmacological Treatment Type: Acupressure, Aromatherapy, Hypnotherapy, Electroacupuncture, Ginger Supplements

6) By Other Treatment Types: Antihistamines, Anticholinergics, Cannabinoids, Combination Therapy, Herbal & Natural Remedies

What Trends Are Expected To Impact The Competitive Landscape Of The Post-Operative Nausea And Vomiting Market?

Key players in the post-operative nausea and vomiting market are concentrating on developing crucial injectable medications, exemplified by the commercial introduction of regulatory-approved pharmaceutical injectables designed to improve antiemetic therapy in clinical environments. A regulatory-approved commercial launch of such an injectable signifies the market release of an FDA- or authority-approved drug for clinical application, following the completion of all necessary regulatory approvals and compliance protocols. For example, in July 2024, Avenacy, a US-based specialty pharmaceutical company, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials, aiming to assist healthcare providers in reducing dosing errors and enhancing patient safety. This injection is approved for preventing nausea and vomiting induced by chemotherapy and for managing postoperative nausea and vomiting (PONV) for up to 24 hours after surgery, thereby providing a trustworthy treatment solution for patients susceptible to these conditions.

Which Major Industry Participants Are Leading The Post-Operative Nausea And Vomiting Market Growth?

Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc., Helsinn Healthcare SA, Heron Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Johnson And Johnson, Sanofi, Aurobindo Pharma Ltd., Lupin Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/post-operative-nausea-and-vomiting-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Post-Operative Nausea And Vomiting Market?

North America was the largest region in the post-operative nausea and vomiting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Post-Operative Nausea And Vomiting Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp

Browse Through More Reports Similar to the Global Post-Operative Nausea And Vomiting Market 2026, By The Business Research Company

Intraoperative Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/intraoperative-imaging-global-market-report

Hospice Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospice-care-global-market-report

Acute Pancreatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795